Nuvation Bio Secures $287.5M in Convertible Notes as Underwriters Fully Exercise Greenshoe Option
NUVB has more than doubled off its 52-week low of $2.01.
Summary
Nuvation Bio has completed its convertible senior notes offering, with underwriters fully exercising the greenshoe option to raise a total of $287.5 million. This follows the initial announcement of a $200 million offering on June 25th and its upsizing to $250 million on June 26th. The full exercise indicates strong market demand for the notes. The company expects to receive approximately $277.6 million in net proceeds, significantly boosting its cash reserves for general corporate purposes.
At the time of this announcement, NUVB was trading at $5.51 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $2.01 to $9.75. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: PR Newswire.